SAN DIEGO, Oct. 18 /PRNewswire/ -- MediVas, LLC, today announced promising data from a preclinical H5N1 vaccine study in ferrets performed at Battelle Memorial Institute’s Medical Research and Evaluation Facility in Columbus, Ohio. For this study, MediVas utilized its novel, synthetic subunit vaccine, which provides an alternative to traditional egg-based vaccines. The vaccine used the company’s patented biodegradable polymer technology in a particle form with purified recombinant hemagglutinin (HA) and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. This technology allows MediVas to produce a vaccine against any mutated influenza virus in as a short as five weeks.
Commenting on the results, Kenneth W. Carpenter, MediVas’ President and CEO said, “These outstanding results represent a significant achievement in the development of our next-generation pandemic flu vaccine. These data validate our novel technology and, in particular, our lead intranasal formulation, which showed a 100% survival rate, presents a meaningful advance in vaccine technology. With the high antibody response and exceptional survival results achieved across all formulations in this study, coupled with our ability for low cost manufacture, storage and transport of our subunit vaccines, MediVas is poised to deliver a breakthrough in the fight against avian and seasonal flu.”
About MediVas: Since its founding in 1998, MediVas has had one simple goal -- to change the way that pharmaceuticals are delivered. From small molecule drugs to whole proteins, MediVas has developed a novel platform technology that provides solutions to meet each challenge. MediVas polymers are the first of a new generation of absorbable and biocompatible drug and biologic delivery platforms. MediVas is utilizing its novel polymer technology in collaboration with some of the world’s largest pharmaceutical and medical device companies, as well as our own internal product development efforts. Using this platform technology, MediVas is currently focusing its development efforts on the delivery of biologics.
Contact: MediVas, LLC Victor E. Vilaplana Director, Business Development (858) 622-2005 vvilaplana@medivas.com
MediVas, LLC
CONTACT: Victor E. Vilaplana, Director, Business Development of MediVas,LLC, +1-858-622-2005, vvilaplana@medivas.com
